8-K: Allogene Therapeutics to Restate Financials Due to Accounting Error in Joint Venture

Allogene Therapeutics will restate its financial statements from 2020 to 2023 due to an accounting error related to its joint venture, Allogene Overland Biopharm.

Summary

• Allogene Therapeutics received comments from the SEC regarding its accounting for its joint venture, Allogene Overland Biopharm.
• The company initially recorded its investment in Allogene Overland at zero, but it should have been measured at fair value.
• This error requires a restatement of financial statements for the years 2020, 2021, and 2022, as well as quarterly reports in 2021, 2022, and 2023.
• The restatement will include recording the fair value of the initial investment and additional revenue from the license agreement.
• The company will also record its share of net losses from Allogene Overland.
• The restatement is non-cash and will not impact the company's cash flow.
• The company has identified a material weakness in internal control over financial reporting.
• The company aims to complete the restatement and file an amended 2022 Form 10-K by March 14, 2024.

Sentiment

Score: 3

Explanation: The document reveals a significant accounting error and a material weakness in internal controls, which are negative signals for investors. While the restatement is non-cash, the loss of confidence in previously reported financials is a major concern.

Positives

• The restatement is non-cash and will not impact the company's cash flow or cash reserves.
• The company is taking steps to remediate the identified material weakness in internal control over financial reporting.
• The company is targeting a relatively quick turnaround for the restatement, aiming for a March 14, 2024 filing.

Negatives

• The company's financial statements for 2020, 2021, and 2022, and subsequent quarterly reports, can no longer be relied upon.
• A material weakness in internal control over financial reporting has been identified.
• The company's independent auditor's report on internal control over financial reporting as of December 31, 2022, should no longer be relied upon.

Risks

• The completion of the restatement analysis and financial close process could take longer than expected.
• The restatement could reveal additional accounting issues or material weaknesses.
• The restatement could negatively impact investor confidence and the company's stock price.
• There is a risk that the company may not meet the March 14, 2024 deadline for filing the restated financials.

Future Outlook

The company expects to complete the restatement analysis and present restated financials for impacted periods in an amendment to the FY 2022 Form 10-K, and restate subsequent interim period financials, as soon as reasonably practicable, targeting on or before March 14, 2024 for such filing.

Management Comments

• The Audit Committee determined that the Seed Preferred Shares should have been initially measured at fair value, and the accounting for the Seed Preferred Shares should be restated.
• The company's management has concluded that the company's disclosure controls and procedures were not effective at the reasonable assurance level.
• The company's internal control over financial reporting was not effective as of the end of each of the periods covered by the restatement.

Industry Context

This announcement highlights the complexities of accounting for joint ventures, particularly in the biotechnology sector where licensing agreements and equity investments are common. It underscores the importance of accurate financial reporting and internal controls.

Comparison to Industry Standards

• Restatements due to accounting errors are not uncommon in the biotech industry, particularly for companies with complex collaborations and joint ventures.
• Companies like Adaptimmune Therapeutics and bluebird bio have also faced accounting challenges related to collaborations and licensing agreements.
• The materiality of the error and the speed of remediation will be key factors in how investors view Allogene's situation compared to industry peers.
• The impact of the restatement on Allogene's financial metrics will be closely watched by analysts and investors to assess its impact on the company's valuation.

Related Party Transactions

• The document details transactions between Allogene Therapeutics and its joint venture, Allogene Overland Biopharm, which is considered a related party.

Stakeholder Impact

• Shareholders will be impacted by the restatement and the potential for a negative impact on the stock price.
• Employees may be affected by the internal control issues and the need for remediation.
• Creditors may be concerned about the reliability of the company's financial statements.
• Customers and suppliers may be indirectly affected by the company's financial situation.

Next Steps

• The company will complete the restatement analysis.
• The company will present restated financials for impacted periods in an amendment to the FY 2022 Form 10-K.
• The company will restate subsequent interim period financials.
• The company will remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

restatement, financial statements, accounting error, joint venture, Allogene Overland, internal control, material weakness, SEC, audit, financial reporting